Hangzhou Biotest Biotech Hits Day High with 8.82% Surge

Hangzhou Biotest Biotech Co., Ltd. has experienced a significant uptick in its stock performance, gaining 8.82% on June 10, 2026. The stock reached an intraday high of CNY 40.36, marking a notable achievement for the small-cap company in the pharmaceuticals and biotechnology sector. In comparison to the broader market, Hangzhou Biotest's one-day performance stands out against the China Shanghai Composite, which declined by 0.42%. Over the past week, the company has also shown resilience with a 4.75% increase, while the Shanghai Composite fell by 2.22%. Despite these short-term gains, the company has faced challenges in its long-term growth metrics. Over the last five years, net sales have decreased at an annual rate of 38.86%, and operating profit has dropped by 63.30%. The company's current market capitalization is CNY 5,298 million, with a price-to-earnings ratio of 188.00. As Hangzhou Biotest Biotech Co. continues to navigate its market position, today's performance highlights its ability to achieve intraday highs amidst a fluctuating market environment.